Clinical trial optimization solutions for pharma and CRO
Most clinical trials don't fail because of bad science. They fail because of avoidable operational problems: enrollment shortfalls that were predictable, country strategies locked in spreadsheets, protocol reviews that stretch from days into weeks. We build the software and data infrastructure that makes clinical trials faster, more predictable, and easier to run at scale, without cutting corners on compliance.
✔️ AWS Life Sciences Competency Partner
DEFINITION
What is clinical trial optimization?
Clinical trial optimization is the use of data, AI, and engineered workflows to reduce delays, control costs, and improve outcomes across clinical trial design and execution.
It is not a single tool. It spans the full trial lifecycle, from the first feasibility assessment to submission-ready data, and it touches every team involved: clinical operations, data management, regulatory, and sponsors.
ACROSS THE TRIAL
Optimization across the clinical trial lifecycle
Country strategy
Country selection is one of the highest-leverage decisions in trial planning, and one of the most difficult to get right with spreadsheets alone. We model enrollment rates, regulatory timelines, site activation speed, and operational constraints across geographies to identify the right country mix before a trial launches. That means fewer surprises mid-study, more predictable timelines, and a strategy grounded in data rather than institutional knowledge or prior relationships.
Site feasibility and activation
Assessing site performance history, activation timelines, and patient population access using ML models trained on historical data to forecast enrollment by site and population, so sponsors select sites that will deliver on their commitments. Site and country strategy also shapes who can participate in your trial, and under FDA's enrollment diversity guidance and the FDORA Act of 2022, diversity action plans are now a standard submission requirement for Phase III trials. Our enrollment models incorporate demographic access analysis alongside traditional site performance metrics to help you meet that bar.
Protocol design and optimization
Protocol complexity is one of the leading drivers of trial delays and cost overruns. We assess eligibility criteria and endpoints against historical data to catch design issues before they trigger amendment cycles or drive high screen failure rates. Generative AI review then extracts endpoints, flags compliance gaps, and standardizes analysis across reviewers and trials, replacing manual cross-referencing at scale. The result is faster protocol sign-off, fewer late-stage amendments, and a design that holds up through execution.
Operational visibility
Real-time dashboards give sponsors and CROs live visibility into site performance, enrollment trends, and protocol adherence, integrated with your existing CTMS, EDC, and eTMF systems. For decentralized and hybrid trials, we extend that visibility across the full data ecosystem: ePRO/eCOA platforms, eConsent workflows, remote patient monitoring data streams, and wearable device inputs. Whether your trial is site-based, fully decentralized, or a hybrid of both, the operational layer adapts to your model, not the other way around.
INDUSTRY DATA
The cost of doing nothing
$500K lost per day a drug launch is delayed
80% of clinical trials fail to meet enrollment targets on time
The operational problems driving those numbers are well understood. Country strategies built on institutional knowledge. Protocol reviews that stretch from days into weeks. Enrollment shortfalls that were visible in the data months before anyone acted.
What's changed is that the technology to solve them now exists. Machine learning models can forecast enrollment with a precision manual analysis can't match. Experts supported by generative AI tools can review a protocol in hours. Real-time dashboards can surface a site performance problem while there's still time to act.
The organizations moving fastest in clinical development have replaced manual work with systems that are faster, more consistent, and include audit trails that meet 21 CFR Part 11 and ICH E6(R3) requirements, with complete user attribution, timestamps, and change history that hold up under FDA and EMA inspection.
Sources: National Center for Biotechnology Information (NCBI); Applied Clinical Trials
OUR EXPERTISE
How Modus Create helps optimize clinical trials
Clinical trial optimization does not come from a single platform. It comes from improving the systems, workflows, and decisions that determine whether a study stays on time and on budget. This is where we help pharma companies, biotech organizations, and CROs create leverage across the trial lifecycle.
Clinical trial data rarely lives in one place. Enrollment data, CTMS records, EDC data, eTMF documents, site performance metrics, lab results, ePRO/eCOA inputs, IRT/RTSM data, and operational spreadsheets sit in disconnected systems that slow down every decision that depends on them. We design and build the data platforms that unify these sources into a reliable foundation for trial operations, covering system integration, data pipelines, quality controls, and audit trails for regulated environments.
Many clinical teams still run protocol reviews, feasibility assessments, and operational reporting through manual processes and spreadsheet handoffs. Improving clinical trial efficiency requires reducing that manual effort while standardizing execution across teams. We build workflow automation that supports this: automated review pipelines, rules-based task orchestration, and reporting flows that remove bottlenecks without reducing oversight.
The operational problems behind trial delays are often visible in the data before anyone acts on them. Clinical trial analytics makes it possible to identify enrollment risk, underperforming sites, protocol complexity, and review bottlenecks earlier and more consistently than manual analysis allows. We build ML systems that help teams forecast enrollment, evaluate site performance, optimize country strategy, and review trial documents faster. For unstructured content like protocols and supporting documents, we use generative AI to accelerate analysis while keeping human experts in control.
Strong data and models fail when the software around them is hard to use. We design and build interfaces that make complex trial operations easier to manage: internal dashboards for sponsors and CROs, review tools that help teams move faster, and where patient-facing workflows are involved, digital experiences that improve usability and adherence.
Clinical trial systems need to be scalable, secure, and built for compliance from the start, not retrofitted for it. We build cloud-native architectures on AWS that support modern trial operations while meeting the validation, traceability, and audit requirements of regulated life sciences environments.
Decentralized and hybrid trial designs require data architectures that most CTMS platforms were not built to handle. We design and build the integration layer that connects distributed data sources into a unified, audit-ready foundation, with the validation documentation, access controls, and data governance that regulated environments require. The architecture adapts to your trial model, whether site-based, fully decentralized, or hybrid, without creating new compliance risk.
Not sure where to start with clinical trial optimization?
Clinical trial optimization starts with the right decisions, not more software. We help you assess your current setup and define the highest-impact next steps.
CASE STUDIES
Our work in clinical trial optimization
These projects show what's possible when the right systems are built for the right problem.
AI-powered protocol review for a global healthtech firm
A global clinical research and healthcare analytics firm faced critical bottlenecks in protocol reviews that delayed regulatory submissions and postponed patient access to treatments. Manual cross-referencing, fragmented tools, and disconnected databases meant reviews that should take days stretched into weeks.
We built an AI-powered application on AWS that automates protocol analysis, detects compliance gaps, and delivers real-time clinical insights, built on Amazon SageMaker with full GxP compliance from day one.
- 50% reduction in protocol review timelines
- 2x increase in analyst productivity
Clinical trial country strategy automation for a global life sciences firm
Designing country-specific trial strategies required weeks of manual analysis across siloed spreadsheets, with institutional knowledge that lived largely in analysts' heads. Every new constraint meant starting from scratch.
We built an intelligent web application that combines predictive enrollment models with a constraint optimization engine. Analysts can now generate optimized country strategies in minutes, run what-if scenarios instantly, and override AI outputs with their own judgment, with full transparency into the system's reasoning.
- $5M+ saved in clinical trial costs
- Weeks to minutes for country strategy design
OUR APPROACH
Why Modus Create?
We've delivered clinical trial optimization systems for global pharma organizations and CROs who needed something that worked in production, not just in a demo. That means enrollment models that run on your data, protocol review tools that compress weeks into hours, and country strategy systems that replace spreadsheets and institutional knowledge with auditable, repeatable decisions. All built to the GxP standards regulated environments require.
AWS Advanced Tier Partner with Life Sciences Competency
Recognized for delivering compliant cloud projects in regulated environments.
GxP from day one
Audit trails, electronic signatures, and validation documentation ship with every system, not after it.
Your data, your models
We train on your historical trial data, so outputs reflect your therapeutic areas and geographies, not generic industry assumptions.
Full-stack capabilities, one partner
Strategy, data engineering, AI, UX, cloud infrastructure, and GxP validation. All in-house. No integrators, no handoffs between vendors. One accountable partner from discovery to go-live.
Insights from 100+ HCLS Leaders
Turn AI ambition into measurable ROI, without compromising compliance.
This report is built for life sciences leaders:
- Product & digital leaders in pharma, biotech, & medtech
- Clinical, regulatory, & data decision-makers
- Teams scaling AI in highly regulated environments
BY THE NUMBERS
Results from the field
What pharma organizations and CROs have gained by optimizing their clinical trial operations with Modus Create.
LET'S GET STARTED
Talk to Modus Create
Big challenges need bold partners. Let’s talk about where you want to go — and start building the path to get there.
OUR INDUSTRY RESOURCES
Insights on AI and innovation in life sciences
Explore our latest thinking on scaling AI, modernizing platforms, and navigating regulatory complexity in life sciences.
Frequently asked questions
How does AI improve clinical trial design?
AI, particularly machine learning and generative AI, enables clinical teams to move from manual, spreadsheet-based analysis to predictive, scenario-based decision making. ML models trained on historical enrollment data can forecast site performance and patient recruitment. Generative AI can automate protocol review and detect compliance gaps early. The result is faster decisions, fewer errors, and lower trial costs.
What does Modus Create build for clinical trial optimization?
We build custom software and AI systems for pharma companies, biotech firms, and CROs. This includes country strategy and enrollment optimization platforms, AI-powered protocol review tools, and real-time sponsor and site dashboards. Every system is built on your data, integrated with your existing tools, and validated for GxP compliance.
Does Modus Create offer an off-the-shelf clinical trial optimization platform?
No. We build systems tailored to your organization's data, workflows, and regulatory environment. We recognize there are situations in which custom must be the answer. We help you build that custom solution. Every engagement starts with research and discovery to understand your specific challenges before a line of code is written.
How does Modus Create handle GxP compliance in clinical trial software?
GxP compliance, including 21 CFR Part 11 and GCP requirements, is built into our architecture from the start. This includes audit trail design, electronic signature configuration, validation documentation, and data governance. Compliance is a technical requirement, not a checkbox at the end of the project.
What life sciences organizations does Modus Create work with?
We work with global pharmaceutical companies, biotech firms, and CROs, from early-stage biotechs building their first clinical data infrastructure to global pharma organizations modernizing legacy systems at scale.
How does Modus Create handle model explainability for regulatory submissions?
Every model we deploy includes documentation that explains how outputs are generated and what drives each recommendation. For high-stakes decisions, analysts have full visibility into the system's reasoning and can override any output with every action logged in a complete audit trail. This gives your regulatory team what it needs to justify algorithm-assisted decisions in front of the FDA or EMA.
Centralized or decentralized clinical trial: Which model is right for your study?
The right model depends on your therapeutic area, patient population, and regulatory environment. Centralized trials give you tighter control over data collection and site oversight, which matters in early-phase studies or complex procedures that require on-site equipment. Decentralized trials reduce patient burden, expand access to underrepresented populations, and can accelerate enrollment by removing geography as a constraint. Most sponsors today run hybrid models that combine both. The tradeoff in either case is the complexity of your data infrastructure and validation requirements, which is why the technology decisions you make early in trial design have a significant impact on your timeline and costs.
Decentralized and hybrid designs also expand access to underrepresented populations by removing geography as a participation barrier, a consideration now directly relevant to FDA diversity action plan requirements.